An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443

Trial Profile

An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Nusinersen (Primary)
  • Indications Spinal muscular atrophy
  • Focus Adverse reactions
  • Acronyms SHINE
  • Sponsors Biogen; Ionis Pharmaceuticals
  • Most Recent Events

    • 08 Mar 2017 Protocol amended as Planned number of patients changed from 274 to 289,participents are added from (NCT01839656) and number of arms changed from 3 to 4.
    • 02 Mar 2017 Planned number of patients changed from 274 to 289.
    • 02 Mar 2017 Planned End Date changed from 1 Feb 2020 to 1 Aug 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top